Registry-listed formulations

rebimastat · chembl:CHEMBL76222

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 4 completed trials

    Completion Rate
    100%(4/4)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 1/2
    1
    25%
    Phase 2
    2
    50%
    Phase 2/3
    1
    25%

    Phase Distribution

    0

    Early Stage

    4

    Mid Stage

    0

    Late Stage

    Phase Distribution4 total trials
    Phase 1/2Combined phases
    1(25.0%)
    Phase 2Efficacy & side effects
    2(50.0%)
    Phase 2/3Combined phases
    1(25.0%)

    Highest Phase Reached

    Phase 2/3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    4 of 4 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(4)

    Detailed Status

    Completed4

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2/3

    Trials by Phase

    Phase 1/21 (25.0%)
    Phase 22 (50.0%)
    Phase 2/31 (25.0%)

    Trials by Status

    completed4100%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_2_3

    Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

    NCT00006229
    completedphase_2

    Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

    NCT00039104
    completedphase_1_2

    BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

    NCT00024024
    completedphase_2

    BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

    NCT00040755

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT00006229Phase 2/3

    Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

    Completed
    NCT00039104Phase 2

    Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

    Completed
    NCT00024024Phase 1/2

    BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

    Completed
    NCT00040755Phase 2

    BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Drug
    Molecule Type
    Small molecule
    Total Trials
    4

    External References

    ChEMBL
    CHEMBL76222

    Names & Codes

    Research Codes

    BMS 275291-01BMS-275291D-2163